Literature DB >> 17072953

Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors.

Ikuo Nagashima1, Tadahiro Takada, Miki Adachi, Hirokazu Nagawa, Tetsuichiro Muto, Kota Okinaga.   

Abstract

AIM: To select accurately good candidates of hepatic resection for colorectal liver metastasis.
METHODS: Thirteen clinicopathological features, which were recognized only before or during surgery, were selected retrospectively in 81 consecutive patients in one hospital (Group I). These features were entered into a multivariate analysis to determine independent and significant variables affecting long-term prognosis after hepatectomy. Using selected variables, we created a scoring formula to classify patients with colorectal liver metastases to select good candidates for hepatic resection. The usefulness of the new scoring system was examined in a series of 92 patients from another hospital (Group II), comparing the number of selected variables.
RESULTS: Among 81 patients of Group I, multivariate analysis, i.e. Cox regression analysis, showed that multiple tumors, the largest tumor greater than 5 cm in diameter, and resectable extrahepatic metastases were significant and independent prognostic factors for poor survival after hepatectomy (P < 0.05). In addition, these three factors: serosa invasion, local lymph node metastases of primary cancers, and post-operative disease free interval less than 1 year including synchronous hepatic metastasis, were not significant, however, they were selected by a stepwise method of Cox regression analysis (0.05 < P < 0.20). Using these six variables, we created a new scoring formula to classify patients with colorectal liver metastases. Finally, our new scoring system not only classified patients in Group I very well, but also that in Group II, according to long-term outcomes after hepatic resection. The positive number of these six variables also classified them well.
CONCLUSION: Both, our new scoring system and the positive number of significant prognostic factors are useful to classify patients with colorectal liver metastases in the preoperative selection of good candidates for hepatic resection.

Entities:  

Mesh:

Year:  2006        PMID: 17072953      PMCID: PMC4088138          DOI: 10.3748/wjg.v12.i39.6305

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Indicators for treatment strategies of colorectal liver metastases.

Authors:  H Ueno; H Mochizuki; K Hatsuse; K Hase; T Yamamoto
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases.

Authors:  B Cady; M D Stone; W V McDermott; R L Jenkins; A Bothe; P T Lavin; E J Lovett; G D Steele
Journal:  Arch Surg       Date:  1992-05

3.  Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy.

Authors:  Y Sugawara; J Yamamoto; S Yamasaki; K Shimada; T Kosuge; M Makuuchi
Journal:  Surgery       Date:  2001-04       Impact factor: 3.982

Review 4.  Resection of hepatic metastases from colorectal cancer. Biologic perspective.

Authors:  G Steele; T S Ravikumar
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

5.  Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.

Authors:  L P Fielding; R Hittinger; R H Grace; J S Fry
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

Review 6.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases.

Authors: 
Journal:  Surgery       Date:  1988-03       Impact factor: 3.982

7.  Analysis of hepatic recurrence of colorectal cancer after resection of hepatic metastases.

Authors:  A Yamaguchi; Y Kurosaka; M Kanno; Y Yonemura; R Izumi; K Miwa; I Miyazaki
Journal:  Int Surg       Date:  1993 Jan-Mar

8.  One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants.

Authors:  R Doci; L Gennari; P Bignami; F Montalto; A Morabito; F Bozzetti
Journal:  Br J Surg       Date:  1991-07       Impact factor: 6.939

9.  The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases.

Authors:  R N Younes; A Rogatko; M F Brennan
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

Review 10.  Surgical treatment of liver metastases in patients with colorectal cancer.

Authors:  G H Ballantyne; J Quin
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

View more
  11 in total

1.  FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis.

Authors:  Akira Watanabe; Norifumi Harimoto; Takehiko Yokobori; Kenichiro Araki; Norio Kubo; Takamichi Igarashi; Mariko Tsukagoshi; Norihiro Ishii; Takahiro Yamanaka; Tadashi Handa; Tetsunari Oyama; Tetsuya Higuchi; Ken Shirabe
Journal:  Int J Clin Oncol       Date:  2019-10-14       Impact factor: 3.402

2.  Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection.

Authors:  Universe Leung; Mithat Gönen; Peter J Allen; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

3.  D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer.

Authors:  Akira Watanabe; Kenichiro Araki; Norihumi Harimoto; Norio Kubo; Takamichi Igarashi; Norihiro Ishii; Takahiro Yamanaka; Kei Hagiwara; Hiroyuki Kuwano; Ken Shirabe
Journal:  Int J Clin Oncol       Date:  2018-03-24       Impact factor: 3.402

4.  Extended pathology reporting of resection specimens of colorectal liver metastases: the significance of a tumour pseudocapsule.

Authors:  Matthew G Wiggans; Golnaz Shahtahmassebi; Paul Malcolm; Frances McCormick; Somaiah Aroori; Matthew J Bowles; David A Stell
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

Review 5.  Multisciplinary management of patients with liver metastasis from colorectal cancer.

Authors:  Kathleen De Greef; Christian Rolfo; Antonio Russo; Thiery Chapelle; Giuseppe Bronte; Francesco Passiglia; Andreia Coelho; Konstantinos Papadimitriou; Marc Peeters
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

6.  Lymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis.

Authors:  Jannemarie A M de Ridder; Nikki Knijn; Bastiaan Wiering; Johannes H W de Wilt; Iris D Nagtegaal
Journal:  Ann Surg Oncol       Date:  2015-05-19       Impact factor: 5.344

7.  Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases.

Authors:  Kerstin Wimmer; Christoph Schwarz; Carmen Szabo; Martin Bodingbauer; Dietmar Tamandl; Martina Mittlböck; Klaus Kaczirek
Journal:  Ann Surg Oncol       Date:  2016-10-11       Impact factor: 5.344

Review 8.  Multidisciplinary approach of colorectal cancer liver metastases.

Authors:  Giammaria Fiorentini; Donatella Sarti; Camillo Aliberti; Riccardo Carandina; Andrea Mambrini; Stefano Guadagni
Journal:  World J Clin Oncol       Date:  2017-06-10

9.  Hepatic resection after neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer: need for cautious planning.

Authors:  Young Il Kim; In Ja Park; Jeong Eun Kim; So Yeon Kim; Jin-Hong Park; Jae Hoon Lee; Tae Yong Ha; Yong Sang Hong; Sun Young Kim; Tae Won Kim; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim
Journal:  Ann Surg Treat Res       Date:  2019-11-01       Impact factor: 1.859

Review 10.  Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer.

Authors:  Gloria Chan; Cheng E Chee
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.